Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK)
HKD 0.63
(0.0%)
HKD 0.63
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.86 Billion CNY | -14.7% |
| 2022 | 2.18 Billion CNY | -28.21% |
| 2021 | 3.03 Billion CNY | 23.3% |
| 2020 | 2.46 Billion CNY | -14.39% |
| 2019 | 2.87 Billion CNY | -1.34% |
| 2018 | 2.91 Billion CNY | 6.25% |
| 2017 | 2.74 Billion CNY | -13.81% |
| 2016 | 3.18 Billion CNY | 0.58% |
| 2015 | 3.16 Billion CNY | 2.69% |
| 2014 | 3.08 Billion CNY | -34.83% |
| 2013 | 4.73 Billion CNY | 55.55% |
| 2012 | 3.04 Billion CNY | 35.7% |
| 2011 | 2.24 Billion CNY | 116.23% |
| 2010 | 1.03 Billion CNY | 46.26% |
| 2009 | 708.9 Million CNY | 38.99% |
| 2008 | 510.04 Million CNY | 78.12% |
| 2007 | 286.34 Million CNY | 77.0% |
| 2006 | 161.77 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 949.69 Million CNY | 0.0% |
| 2023 FY | 1.86 Billion CNY | -14.7% |
| 2023 Q2 | 1.05 Billion CNY | 0.0% |
| 2023 Q4 | 804.83 Million CNY | 0.0% |
| 2022 FY | 2.18 Billion CNY | -28.21% |
| 2022 Q2 | 1.46 Billion CNY | 0.0% |
| 2021 FY | 3.03 Billion CNY | 23.3% |
| 2021 Q2 | 1.9 Billion CNY | 0.0% |
| 2020 Q2 | 1.05 Billion CNY | 0.0% |
| 2020 Q4 | 1.4 Billion CNY | 0.0% |
| 2020 FY | 2.46 Billion CNY | -14.39% |
| 2019 Q4 | 1.22 Billion CNY | 0.0% |
| 2019 Q2 | 1.65 Billion CNY | 0.0% |
| 2019 FY | 2.87 Billion CNY | -1.34% |
| 2018 FY | 2.91 Billion CNY | 6.25% |
| 2018 Q4 | 1.63 Billion CNY | 0.0% |
| 2018 Q2 | 1.27 Billion CNY | 0.0% |
| 2017 Q2 | 1.44 Billion CNY | 0.0% |
| 2017 Q4 | 1.3 Billion CNY | 0.0% |
| 2017 FY | 2.74 Billion CNY | -13.81% |
| 2016 Q2 | 1.38 Billion CNY | 0.0% |
| 2016 FY | 3.18 Billion CNY | 0.58% |
| 2016 Q4 | 1.79 Billion CNY | 0.0% |
| 2015 Q4 | 1.39 Billion CNY | 0.0% |
| 2015 FY | 3.16 Billion CNY | 2.69% |
| 2015 Q2 | 1.77 Billion CNY | 0.0% |
| 2014 FY | 3.08 Billion CNY | -34.83% |
| 2014 Q4 | 1.7 Billion CNY | 0.0% |
| 2014 Q2 | 1.38 Billion CNY | 0.0% |
| 2013 FY | 4.73 Billion CNY | 55.55% |
| 2013 Q4 | 261.65 Million CNY | -77.89% |
| 2013 Q3 | 1.18 Billion CNY | -49.11% |
| 2013 Q2 | 2.32 Billion CNY | 96.48% |
| 2013 Q1 | 1.18 Billion CNY | 0.0% |
| 2012 Q4 | 1.18 Billion CNY | 55.55% |
| 2012 FY | 3.04 Billion CNY | 35.7% |
| 2012 Q2 | 760.63 Million CNY | 0.0% |
| 2012 Q1 | 760.63 Million CNY | 0.0% |
| 2012 Q3 | 760.63 Million CNY | 0.0% |
| 2011 Q4 | 760.63 Million CNY | 35.7% |
| 2011 Q3 | 560.51 Million CNY | 0.0% |
| 2011 Q2 | 560.51 Million CNY | 0.0% |
| 2011 Q1 | 560.51 Million CNY | 0.0% |
| 2011 FY | 2.24 Billion CNY | 116.23% |
| 2010 Q4 | 560.51 Million CNY | 116.23% |
| 2010 FY | 1.03 Billion CNY | 46.26% |
| 2010 Q1 | 259.22 Million CNY | 0.0% |
| 2010 Q2 | 259.22 Million CNY | 0.0% |
| 2010 Q3 | 259.22 Million CNY | 0.0% |
| 2009 Q4 | 259.22 Million CNY | 46.26% |
| 2009 FY | 708.9 Million CNY | 38.99% |
| 2009 Q3 | 177.22 Million CNY | 0.0% |
| 2009 Q2 | 177.22 Million CNY | 0.0% |
| 2009 Q1 | 177.22 Million CNY | 0.0% |
| 2008 Q3 | 127.51 Million CNY | 0.0% |
| 2008 Q1 | 127.51 Million CNY | 0.0% |
| 2008 FY | 510.04 Million CNY | 78.12% |
| 2008 Q2 | 127.51 Million CNY | 0.0% |
| 2008 Q4 | 177.22 Million CNY | 38.99% |
| 2007 Q2 | 71.58 Million CNY | 0.0% |
| 2007 Q1 | 71.58 Million CNY | 0.0% |
| 2007 Q3 | 71.58 Million CNY | 0.0% |
| 2007 FY | 286.34 Million CNY | 77.0% |
| 2007 Q4 | 127.51 Million CNY | 78.12% |
| 2006 FY | 161.77 Million CNY | 0.0% |
| 2006 Q1 | 40.44 Million CNY | 0.0% |
| 2006 Q3 | 40.44 Million CNY | 0.0% |
| 2006 Q4 | 71.58 Million CNY | 77.0% |
| 2006 Q2 | 40.44 Million CNY | 0.0% |
| 2005 Q4 | 40.44 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -617.917% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 82.33% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -3048.227% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -137.35% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -93.546% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -76.684% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -9.023% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -129.95% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -357.293% |
| SSY Group Limited | 6.46 Billion HKD | 71.212% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -186.936% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -26.757% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.312% |